Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab

PURPOSE: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) following pembrolizumab treatment in melanoma patients. EXPERIMENTAL DES...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria, Brenner, Nicole, Kähler, Katharina, Heinzerling, Lucie, Gutzmer, Ralf, Bender, Armin, Gebhardt, Christoffer, Romano, Emanuela, Meier, Friedegund, Martus, Peter, Maio, Michele, Blank, Christian, Schadendorf, Dirk, Dummer, Reinhard, Ascierto, Paolo A., Hospers, Geke, Garbe, Claus, Wolchok, Jedd D.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572569/
https://ncbi.nlm.nih.gov/pubmed/27185375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0127
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk